Pfizer offers a high 6.19% dividend yield, attractive to income investors, but the sustainability of this payout is uncertain due to upcoming patent expirations that threaten revenue. The company covers dividends with free cash flow, but the margin is thin, and buybacks have been paused to preserve cash. New product launches show growth but have yet to fully replace lost COVID-19 related revenues. Pfizer's significant debt and tight cash flow coverage mean any sustained drop in operating cash flow could pressure the dividend in the future.
Pfizer shares are trading at USD 28.06 on Pluang as of Sep 14, 2026 20:32 WIB, showing a 1.23% gain for the day. The stock offers a dividend yield of 6.2%, closely matching the article's reported 6.19%. Its market capitalization stands at $157.99 billion, reflecting significant investor interest despite concerns about dividend sustainability.
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite...
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
